TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00991003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy
Description: The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Colonoscopy
Study: NCT03879577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered to all patients for a minimum of 4 cycles for 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Herceptin
Description: Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.

Intervention type: DRUG
Group type: OTHER
Intervention: FEC
Description: Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.

Intervention type: DRUG
Group type: OTHER
Intervention: LHRH agonist
Description: Administered to all premenopausal patients.
Study: NCT00686218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given orally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Testing

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Testing

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Testing
Study: NCT01684033

Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue™ MPS

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue™ MPS

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lenses
Description: Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lenses
Description: Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
Study: NCT02405065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
Study: NCT02687165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran and D-cycloserine
Description: Milnacipran augmented by D-cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran and D-cycloserine
Description: Milnacipran augmented by D-cycloserine
Study: NCT03833843

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: ECG, Echocardiography and cardiac magnetic resonance imaging
Study: NCT00002836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: As part of CVP chemotherapy treatment by vein (IV) on days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.
Study: NCT03084679

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise in treadmill
Description: 30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise in treadmill
Description: 30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.

Intervention type: OTHER
Group type: OTHER
Intervention: Local strengthening exercises
Description: 15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.

Intervention type: OTHER
Group type: OTHER
Intervention: Local strengthening exercises
Description: 15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.

Intervention type: OTHER
Group type: OTHER
Intervention: Stretching exercises
Description: 5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)

Intervention type: OTHER
Group type: OTHER
Intervention: Stretching exercises
Description: 5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
Study: NCT00682435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?
Study: NCT00289900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study: NCT03685435

Intervention type: OTHER
Intervention: Bedside ultrasound
Description: Checking for gastric content using bedside ultrasound
Study: NCT02516111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by Open flap debridement (OFD)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OFD with PRF
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OFD with ALN
Description: Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OFD with ATV
Description: Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
Study: NCT03607058

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinect + Exercise Training
Description: Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
Study: NCT00992394

Intervention type: DRUG
Group type: OTHER
Intervention: etanercept
Description: etanercept 50 mg once weekly as requested.

Intervention type: DRUG
Group type: OTHER
Intervention: etanercept
Description: etanercept 25 mg or 50 mg as requested.
Study: NCT01981993

Intervention type: BIOLOGICAL
Intervention: Urinary proteomic analysis
Study: NCT04588363

Intervention type: OTHER
Intervention: SARS-CoV-2 and/or MIS-C Exposure
Description: This is an observational cohort study.
Study: NCT02568254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 1 (etafilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 1 (etafilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 1 (etafilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 1 (etafilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 1 (etafilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 1 (etafilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 2 (nelfilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 2 (nelfilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 2 (nelfilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 2 (nelfilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 2 (nelfilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 2 (nelfilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 3 (nesofilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 3 (nesofilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 3 (nesofilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 3 (nesofilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 3 (nesofilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 3 (nesofilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Study: NCT01253356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IABP
Description: Insertion of intra-aortic balloon \< or = 3 hours before noncardiac surgery and maintained \> or = 12-24 hours after surgery
Study: NCT04375215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective caries removal
Description: After caries removal restoration of tooth will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise caries removal
Description: After caries removal restoration of tooth will be performed
Study: NCT03456297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based clinical pedagogy program (WCP)
Description: The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
Study: NCT01565694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral suspension administered once a day via syringe.
Study: NCT03511209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI plus taper method A
Description: This intervention includes CBTI plus the novel hypnotic tapering method.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI plus taper method B
Description: This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
Study: NCT01787903

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Real-time continuous glucose monitor
Description: Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time continuous glucose monitor
Description: Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
Study: NCT04901052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 supplementation group
Description: n-3 supplementation group (1.5g of omega 3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group (sunflower oil)
Study: NCT02857920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 7.5 mg/kg, i.v, once every 3 weeks (continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg, i.v, once every 3 weeks (continuous)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.
Study: NCT01778985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00723944

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite Certain Prevail
Description: Root form titanium dental implant

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Osseotite Certain
Description: Dental implant without the lateralized design
Study: NCT01382407

Intervention type: DRUG
Intervention: Cetuximab
Description: Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
Study: NCT01446588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: Three yoga classes per week for 8 weeks.
Study: NCT00284934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: At a dose of at least 5 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: At a dose of at least 5 mg/day.
Study: NCT03554109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: albumin-binding prodrug of doxorubicin HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin HCL
Description: Doxorubicin HCL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel
Study: NCT04568772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atovaquone / Proguanil 250/100 mg
Description: Atovaquone / Proguanil 250/100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil 250/100 mg
Description: Atovaquone / Proguanil 250/100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil 250/100 mg
Description: Atovaquone / Proguanil 250/100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil 250/100 mg
Description: Atovaquone / Proguanil 250/100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Esomeprazole 40 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Description: Vonoprazan 20 mg tablet